FDA Approves AstraZeneca's Fasenra (Benralizumab) For Add-on Maintenance Treatment For Patients With Severe Asthma Aged 6 To 11 With An Eosinophilic Phenotype
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved AstraZeneca's Fasenra (Benralizumab) for add-on maintenance treatment for severe asthma in patients aged 6 to 11 with an eosinophilic phenotype. This expands its previous approval for patients aged 12 and older.
April 11, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Fasenra receives FDA approval for expanded use in children aged 6 to 11 with severe eosinophilic asthma, broadening its patient base.
The FDA approval for expanded use of Fasenra in a younger patient demographic can potentially increase AstraZeneca's market share and revenue from this product. This regulatory milestone is significant as it opens up a new patient segment for Fasenra, which was previously approved only for patients aged 12 and older. The approval is based on the drug's efficacy and safety profile, indicating a positive impact on AstraZeneca's product portfolio and possibly its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100